Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;309(6):2307-2313.
doi: 10.1007/s00404-024-07408-2. Epub 2024 Mar 19.

PCOS phenotype focus: phenotype D under the magnifying glass

Samuel H Myers  1 , Mario Montanino Oliva  2   3 , Maurizio Nordio  2   4 , Vittorio Unfer  5   6
Affiliations
Review

PCOS phenotype focus: phenotype D under the magnifying glass

Samuel H Myers et al. Arch Gynecol Obstet. 2024 Jun.

Abstract

Polycystic ovary syndrome (PCOS) is defined as the combination of polycystic morphology, hyperandrogenism, and ovulatory disruption; this heterogeneity presents a conundrum for the medical community. The Rotterdam criteria have governed the diagnosis of PCOS, separating the patient cohort into four distinct phenotypes. It has been suggested that the lone normoandrogenic phenotype, so-called phenotype D, should not be classified as a PCOS subtype, with phenotypes A, B, and C displaying a hyperandrogenic biochemical and clinical profile thought to be characteristic of PCOS. To understand how to treat phenotype D patients, this review shines a spotlight on the phenotype, gathering various reports of how phenotype D is differentiated from the other PCOS phenotypes.

Keywords: Assisted reproductive technology (ART); Hyperandrogenism; PCOS phenotype D; PCOS phenotype prevalence; Polycystic ovary syndrome; Rotterdam criteria.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rodriguez Paris V, Bertoldo MJ (2019) The mechanism of androgen actions in PCOS etiology. Med Sci 7(9):89
    1. Hoeger KM, Dokras A, Piltonen T (2021) Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab 106(3):e1071–e1083. https://doi.org/10.1210/clinem/dgaa839 - DOI - PubMed
    1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W et al (2006) Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91(11):4237–4245. https://doi.org/10.1210/jc.2006-0178 - DOI - PubMed
    1. Azziz R (2021) How polycystic ovary syndrome came into its own. F S Sci 2(1):2–10. https://doi.org/10.1016/j.xfss.2020.12.007 - DOI - PubMed
    1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7. doi: https://doi.org/10.1093/humrep/deh098 .

LinkOut - more resources